Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
The Effect of Synbiotic Consumption on Glycemic, Inflammatory Markers and Body Composition on Prediabetic and Diabetic Patients: A Double Blinded Randomized Control Trial	Imam Abdulrahman Bin Faisal University	Ongoing	Synbiotics (Viridian Nutrition)	3	IRB-2019-03-227	King Fahad University Hospital (Al-Khobar) , Family and Community Medicine Center (Dammam)
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS	Pfizer	Terminated	Abrocitinib	3	B7451064	King Abdulaziz University Hospital (Jeddah)
A randomized, double-blind, placebo controlled study assessing the long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate to severe asthma	Sanofi Aventis	Ongoing	Dupilumab	4	LPS16676	King Saud Medical City (Riyadh),King Abdullah Medical City (Makkah)
Effectiveness of Dextrose 5% In Water Local Injection Into Spastic Muscles to manage focal Spasticity (D5W/ Spasticity ).	PI-initiated	Rejected	DEXTROSE 5% IN WATER	4	TU022144	King Fahad specialized hospital (Tabuk)
The effects of alpha lipoic acid supplementation on nerve conduction study in patients with diabetic neuropathy	EVA PHARMA	Rejected	ALPHA LIPOIC ACID	4	IRB-2022-5	King Fahad University Hospital (Al-Khobar)
Transthyretin Amyloidosis Outcomes Survey (THAOS): A Global, Multi-Center, Longitudinal, Observational Survey of Patients With Documented Transthyretin Gene Mutations or Wild-Type Transthyretin Amyloidosis	Pfizer	Terminated	Tafamidis	4	B3461001	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease	Agios Pharmaceuticals, Inc.	Ongoing	Mitapivat	2/3	AG348-C-020	King Khalid University Hospital (Riyadh)
Prospective, observational study in sickle cell disease patients on crizanlizumab treatment in Middle East countries and India.	Novartis	Ongoing	crizanlizumab	4	CSEG101AIC05	Prince Mohammad Bin Naser Hospital, Jizan, Saudi Arabia
A PHASE II, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER PLATINUM-BASED CONCURRENT CHEMORADIATION	Roche	Ongoing	ATEZOLIZUMAB (TECENTRIQ)	2	MO43156	King Fahad Specialist Hospital (Dammam)
A randomized, sham-controlled, double-blind study to evaluate the efficacy and safety of intrathecal (IT) OAV101 in patients with later onset Type 2 spinal muscular atrophy (SMA) who are ≥ 2 to < 18 years of age, treatment naive, sitting, and never ambulatory	Novartis Saudi Limited	Ongoing	OAV101 (formerly AVXS-101)	3	COAV101B12301	King Faisal Specialist Hospital and Research Center (Riyadh),King Fahad Specialist Hospital (Dammam)